Evidence map›Paper›PMID 39110155›Full record

ArticleCornea2024

Accuracy and Completeness of Large Language Models About Antibody-Drug Conjugates and Associated Ocular Adverse Effects.

Rayna Marshall, Hannah Xu, Lauren A Dalvin, Kapil Mishra, Camellia Edalat, Nila Kirupaharan, Jasmine H Francis, Meghan Berkenstock

Abstract read
In one paragraph

Article in Cornea, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rayna MarshallDrexel University College of Medicine, Philadelphia, PA.ORCID 0000-0002-6961-1278
Hannah XuUniversity of California San Diego, San Diego, CA.
Lauren A DalvinMayo Clinic, Rochester, MN.
Kapil MishraUniversity of California Irvine, Irvine, CA.
Camellia EdalatDrexel University College of Medicine, Philadelphia, PA.
Nila KirupaharanDrexel University College of Medicine, Philadelphia, PA.
Jasmine H FrancisMemorial Sloan Kettering Cancer Center, New York, NY; and.
Meghan BerkenstockThe Wilmer Eye Institute, Division of Ocular Immunology, Johns Hopkins University School of Medicine, Baltimore, MD.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Dracopolous Uveitis Research FundNCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeThe purpose of this study was to assess the accuracy and completeness of 3 large language models (LLMs) to generate information about antibody-drug conjugate (ADC)-associated ocular toxicities.

methodsThere were 22 questions about ADCs, tisotumab vedotin, and mirvetuximab soravtansine that were developed and input into ChatGPT 4.0, Bard, and LLaMa. Answers were rated by 4 ocular toxicity experts using standardized 6-point Likert scales on accuracy and completeness. ANOVA tests were conducted for comparison between the 3 subgroups, followed by pairwise t -tests. Interrater variability was assessed with Fleiss kappa tests.

resultsThe mean accuracy score was 4.62 (SD 0.89) for ChatGPT, 4.77 (SD 0.90) for Bard, and 4.41 (SD 1.09) for LLaMA. Both ChatGPT ( P = 0.03) and Bard ( P = 0.003) scored significantly better for accuracy when compared with LLaMA. The mean completeness score was 4.43 (SD 0.91) for ChatGPT, 4.57 (SD 0.93) for Bard, and 4.42 (SD 0.99) for LLaMA. There were no significant differences in completeness scores between groups. Fleiss kappa assessment for interrater variability was good (0.74) for accuracy and fair (0.31) for completeness.

conclusionsAll 3 LLMs had relatively high accuracy and completeness ratings, showing LLMs are able to provide sufficient answers for niche topics of ophthalmology. Our results indicate that ChatGPT and Bard may be slightly better at providing more accurate answers than LLaMA. As further research and treatment plans are developed for ADC-associated ocular toxicities, these LLMs should be reassessed to see if they provide complete and accurate answers that remain in line with current medical knowledge.

Indexed as

Eye DiseasesImmunoconjugatesHumansLarge Language ModelsMaytansineImmunoconjugatesMaytansineantibody drug conjugatesartificial intelligencelarge language modelsmirvetuximab soravtansineocular adverse effectstisotumab vedotin

Identifiers

PMID39110155
PMCPMC12937488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.